紫杉醇或健择联合奥沙利铂治疗非小细胞肺癌的临床对照研究

目的比较健择联合奥沙利铂方案与紫杉醇联合奥沙利铂方案治疗非小细胞肺癌（NSCLC）的疗效及毒副反应。方法选择2003年1月～2009年11月于我院呼吸内科进行化疗的160例Ⅲ～Ⅳ期NSCLC患者,分为健择组及紫杉醇组,两组各80例。紫杉醇组用紫杉醇联合奥沙利铂化疗,健择组用健择醇联合奥沙利铂化疗。结果健择组与紫杉醇组的短期疗效分别为61.3%和45.0%,差异有显著性（P〈0.05）,同时健择组毒副反应发生率较紫杉醇组低。结论健择联合奥沙利铂治疗NSCLC有效率较紫杉醇联合奥沙利铂有效率高,二者之间有显著性差异,且健择联合奥沙利铂方案的毒副作用较少,而且较轻微,故健择联合奥沙利铂方案是治疗NSCLC的较好选择。

A clinical analysis of combined chemotherapy of GEM plus oxaliplatin and palitaxel plus oxaliplatin for non-small cell lung cancer

Objective To observe and compare the efficacy and toxicity of combined chemotherapy regimen of GEM plus Oxaliplatin and Palitaxel plus Oxaliplatin for elderly advanced non-small cell lung cancer（NSCLC）.Methods 160 cases of stage Ⅲ ~ Ⅳ NSCLC were divided into GEM groups and Palitaxel group,80 cases in each group.GEM groups chemotherapy with GEM and Oxaliplatin.Palitaxel group chemotherapy with Palitaxel and Oxaliplatin.Results The short-term efficacy of Gemcitabine group and Palitaxel group were 61.3% and 45%,the difference was significant （P〈0.05）,while gemcitabine group the incidence of side effects was lower than that of Palitaxel.Conclusion The effective rat of Gemcitabine plus oxaliplatin treating of NSCLC are more efficient than that of Palitaxel plus oxaliplatin,the difference between the two groups was significant,and gemcitabine plus oxaliplatin have fewer side effects,but minor,We conclude that GEM plus oxaliplatin treating of NSCLC,the program is the better choice.